Viiv Sailing Study

A Phase III, randonmized, double-blinded study of the safety and efficacy of GSK1349572 50mg once daily versus raltegravir 400 mg twice daily, both administered with an investigator-selected background regimen over 48 weeks in HIV-1 infected, integrase inhibitor-naive, anti retroviral therapy experienced adults. (Open for enrollment).